Skip to content
CA.gov logo in white
  • Grants Management System
  • CIRM Hub Portal
  • Contact
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops
  • About
    • Our Mission
    • Our Impact
    • Our Governing Board
    • Strategic Goals
    • Our Team
    • Annual Reports
  • For Researchers
    • Funding Opportunities
    • Information for Applicants
    • Researcher Resources
    • Our Review Process
  • Our Programs
    • Grants Dashboard
    • Research and Development
    • Education and Training
    • Patient Access
  • Patient Resources
    • Stem Cell and Genetic Research
    • From Bench to Bedside
    • Community Outreach
    • Clinical Trials
    • Community Stories
  • News and Events
    • Press Releases
    • Public Meetings
    • Blog
    • Webinars and Workshops

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingCD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingNonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingStudy Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingCRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingPSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingA Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Post author:
  • Post published:April 20, 2026
  • Post category:

Continue ReadingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
  • Go to the previous page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 22
  • Go to the next page
  • Careers
  • Administrative & Financials
  • Accessibility

Subscribe to Receive CIRM News

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox. 

Sign Up
Facebook-f X-twitter Instagram Linkedin Youtube
  • Privacy Policy
  • ©2025 California Institute for Regenerative Medicine
  • Media Guidelines
  • Contact Us